Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 3/20 | 0.53 |
| ▸ | TERT | O14746 | 5/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 4/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790520 | 0.82 | LTB4R (0.49) | SERPINE1TERTKDM4EHSD17B10 | |
| SCHEMBL6790635 | 0.81 | TERT (0.52) | TERTDHODHKCNK2DEGS1 | |
| SCHEMBL6785899 | 0.78 | TERT (0.54) | TERTDHODHKCNK2KDM4E | |
| SCHEMBL6785956 | 0.77 | TERT (0.53) | TERTDHODHKCNK2KDM4EHSD17B10 | |
| SCHEMBL6783990 | 0.77 | TERT (0.47) | TERTDHODHKCNK2DEGS1 | |
| SCHEMBL4020296 | 0.76 | TERT (0.77) | TERTDHODHKCNK2KDM4EDEGS1 | |
| SCHEMBL6788013 | 0.75 | TERT (0.62) | TERTDHODHKCNK2 | |
| SCHEMBL6781608 | 0.75 | CYP3A4 (0.53) | TERTKCNK2KDM4EHSD17B10 | |
| SCHEMBL6787380 | 0.74 | MEN1 (0.52) | TERTDHODHKCNK2DEGS1 | |
| SCHEMBL6785402 | 0.74 | TERT (0.60) | TERTDHODHKCNK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727250-B2 | ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-04-27 | — | — | US | disclosed |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6362210-B1 | ANTITUMOR, ANTICANCER AGENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | TERT, NAT1, POT1 | SERPINE1 2462/4885TERT 1/4885KDM1A 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.